Semax Mechanism of Action

Introduction

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide classified as a noncorticotropic analog of the ACTH(4-10) melanocortin fragment. Published research has characterized several pharmacological axes through which Semax exerts its reported molecular effects: engagement of central melanocortin receptors, modulation of neurotrophin gene expression (principally BDNF and NGF), and downstream interactions with monoaminergic neurotransmission systems. The following sections summarize findings reported in peer-reviewed primary literature. All conclusions are attributed to the cited source and should be understood as reported experimental observations rather than established clinical facts.

Reported Molecular Interactions with Neurotrophin Systems

The most extensively characterized molecular axis for Semax in published research is its reported interaction with the neurotrophin system — specifically the gene expression and protein levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).

Shadrina and colleagues (2001) published the earliest English-language characterization in Neuroscience Letters, exposing primary rat glial cell cultures to Semax in vitro and measuring neurotrophin mRNA levels at 30 minutes post-treatment [1]. The authors reported approximately eightfold elevation of BDNF mRNA and approximately fivefold elevation of NGF mRNA relative to vehicle controls — a magnitude the authors noted was larger than that observed for other pharmacological agents tested in the same model. This study was conducted in isolated glial cultures from neonatal rat basal forebrain and does not directly establish in vivo or human equivalents. A bibliographic summary of these and subsequent studies is available in the Semax published research article.

Dolotov and colleagues (2006) reported in Brain Research that a single Semax administration in adult rats was associated with approximately 1.4-fold changes in BDNF protein, approximately 3-fold changes in exon III BDNF mRNA, and approximately 2-fold changes in trkB (high-affinity BDNF receptor) mRNA in hippocampal tissue [2]. Tyrosine phosphorylation of trkB — a measure of receptor activation state — was reported to be elevated approximately 1.6-fold. The same group reported in the Journal of Neurochemistry that Semax bound specifically to basal forebrain tissue preparations, with this binding associated with measurable changes in BDNF protein concentrations in those tissues [3].

A subsequent in vivo study by Agapova and colleagues, published in Neuroscience Letters in 2007, examined neurotrophin gene expression in adult rat hippocampus, brainstem, cerebellum, and frontal cortex following intranasal Semax administration [4]. The authors reported region-specific changes in BDNF and NGF mRNA expression, with BDNF gene expression observed to be elevated in hippocampus, brainstem, and cerebellum. The authors concluded that the response was region-specific rather than a uniform transcriptional change across all brain areas.

Dmitrieva and colleagues (2009), published in Cellular and Molecular Neurobiology, characterized the interaction of Semax and its Pro-Gly-Pro metabolite with neurotrophin gene transcription in a rat model of experimental cerebral ischemia [5]. The authors reported that intact Semax showed a selective pattern across neurotrophin gene targets (BDNF, trkB/NTRK2, trkC/NTRK3, trkA/NTRK1, NGF) across 3-, 24-, and 72-hour post-insult time points, while the Pro-Gly-Pro metabolite displayed a comparatively broader, less selective transcriptional profile. This observation was interpreted as indicating that the intact heptapeptide retains a distinct molecular selectivity not fully reducible to its metabolites.

Receptor Target and Melanocortin Pathway

The ACTH(4-10) fragment from which Semax is derived engages the melanocortin receptor (MCR) family — five G-protein-coupled receptor subtypes designated MC1R through MC5R. The central nervous system primarily expresses MC3R and MC4R, and the ACTH(4-10) core is considered the minimal sequence responsible for the behavioral pharmacology attributed to the parent ACTH molecule. Semax retains this core, incorporating the ACTH(4-7) tetrapeptide (Met-Glu-His-Phe) as the pharmacophore and the C-terminal Pro-Gly-Pro tripeptide as a protease-stabilizing extension.

Grivennikov and colleagues (2008) reported in Restorative Neurology and Neuroscience that Semax was associated with approximately 1.5- to 1.7-fold changes in cholinergic neuron survival in rat basal forebrain cultures in vitro [6]. The authors noted that the observed effects appeared to be mediated through a BDNF-dependent mechanism based on the culture conditions examined, consistent with the melanocortin-BDNF pharmacological model. A structurally related compound, N-Acetyl Semax Amidate, has been characterized in separate studies with modifications to both the N-terminus and C-terminus that alter the receptor interaction profile. Research-grade Semax from SpartaLabs is analytically verified by HPLC and mass spectrometry for use in preclinical investigations.

The 2021 study by Filippenkov and colleagues, published in the International Journal of Molecular Sciences, characterized gene expression patterns in rat hippocampus following acute stress exposure and compared several melanocortin derivatives including Semax-related compounds [7]. The authors reported that ACTH(4-10) analogs modulated hippocampal stress-response gene expression without the corticotropic hormonal activity of full-length ACTH — a pharmacological distinction that defines the noncorticotropic melanocortin class.

Downstream Effects Reported in Published Literature

Monoaminergic Systems

Eremin and colleagues (2005) published microdialysis and neurochemical data from rodent experiments in Neurochemical Research, reporting that Semax administration was associated with altered dopamine and serotonin turnover in the striatum, frontal cortex, and hippocampus [8]. The authors measured monoamine metabolites (DOPAC, HVA for dopamine; 5-HIAA for serotonin) using HPLC with electrochemical detection. They proposed that these monoaminergic effects were downstream of melanocortin receptor engagement rather than attributable to direct binding at dopamine or serotonin receptors.

Transcriptome-Level Effects in Ischemia Models

Medvedeva and colleagues (2014) conducted a genome-wide transcriptional analysis in a rat model of permanent middle cerebral artery occlusion (pMCAO), examining differential gene expression in cortical tissue at 3 hours and 24 hours following Semax administration [9]. The study, published in BMC Genomics, identified altered expression of gene sets related to immune response, vascular biology, and inflammatory signaling — with innate immune response pathways and genes associated with blood-brain barrier function showing the most pronounced differential expression at 24 hours.

Copper Coordination

Tabbì and colleagues (2015) reported that Semax forms a stable complex with copper(II) ions through the amino-terminal copper- and nickel-binding (ATCUN) motif contributed by the Met-Glu-His N-terminal sequence [10]. In cell-culture experiments using SH-SY5Y neuroblastoma and RBE4 endothelial cell lines, the Semax-copper complex was reported to attenuate copper-induced cytotoxicity relative to copper alone. The authors proposed that this copper-chelating capacity could have pharmacological relevance in contexts of metal-ion dysregulation.

Opioid Receptor Pathway

Liu and colleagues (2025) published in the British Journal of Pharmacology a study examining Semax in a murine spinal cord injury (SCI) model, focusing on the mu-opioid receptor gene Oprm1 [11]. The researchers reported that Semax was associated with functional recovery outcomes in female mice following SCI and that this was linked to regulation of the USP18 deubiquitinase pathway acting downstream of Oprm1. This pharmacological axis — opioid receptor signaling — had not been previously characterized for Semax, extending the mechanistic literature beyond the established melanocortin-neurotrophin framework.

Areas of Ongoing Investigation

The mechanistic picture for Semax continues to expand through active research. Several aspects of the compound's pharmacology remain under investigation in the published literature:

The identity of the primary receptor subtype(s) responsible for Semax's neurotrophin and monoaminergic effects has not yet been resolved through subtype-selective pharmacological tools. Clarifying the relative contributions of MC3R and MC4R represents a recognized direction for future mechanistic studies.

The metabolic fate of the Pro-Gly-Pro C-terminal tripeptide following Semax administration has been characterized independently, and data from Dmitrieva and colleagues (2009) suggest that the intact heptapeptide retains a pharmacological selectivity profile distinct from its metabolites [5]. The mechanistic basis of this selectivity continues to inform research design.

The pharmacokinetic relationship between administered Semax, CNS bioavailability, and melanocortin receptor occupancy in vivo has not been rigorously quantified in any species, representing an informative frontier for future studies. The 2025 Liu spinal cord injury study, conducted exclusively in female mice, noted sex-specific pharmacological interactions, opening additional dimensions of investigation.

References

1. Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115–8. PMID: 11457573. DOI: 10.1016/S0304-3940(01)01994-2

2. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. PMID: 16996037. DOI: 10.1016/j.brainres.2006.07.108

3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82–6. PMID: 16635254. DOI: 10.1111/j.1471-4159.2006.03658.x

4. Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Kolomin TA, Myasoedov NF, Slominsky PA, Limborska SA. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett. 2007;417(2):201–5. PMID: 17353092. DOI: 10.1016/j.neulet.2007.02.042

5. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71–9. PMID: 19633950. PMCID: PMC11498467. DOI: 10.1007/s10571-009-9432-0

6. Grivennikov IA, Dolotov OV, Zolotarev YA, Andreeva LA, Myasoedov NF, Leacher L, Black IB, Dreyfus CF. Effects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neurons. Restor Neurol Neurosci. 2008;26(1):35–43. PMID: 18431004. DOI: 10.3233/RNN-2008-00419

7. Filippenkov IB, Stavchansky VV, Glazova NYu, Sebentsova EA, Remizova JA, Valieva LV, Levitskaya NG, Myasoedov NF, Limborska SA, Dergunova LV. Antistress action of melanocortin derivatives associated with correction of gene expression patterns in the hippocampus of male rats following acute stress. Int J Mol Sci. 2021;22(18):10054. PMID: 34576218. PMCID: PMC8469576. DOI: 10.3390/ijms221810054

8. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493–500. PMID: 16362768. DOI: 10.1007/s11064-005-8826-8

9. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661604. PMCID: PMC3987924. DOI: 10.1186/1471-2164-15-228

10. Tabbì G, Magrì A, Giuffrida A, Lanza V, Pappalardo G, Naletova I, Nicoletti VG, Attanasio F, Rizzarelli E. Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity. J Inorg Biochem. 2015;142:39–46. PMID: 25310602. DOI: 10.1016/j.jinorgbio.2014.09.014

11. Liu Y, Chen X, Zhang Y, Wang H, Li Z, Wu J, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. PMID: 40692165. DOI: 10.1111/bph.70122